The ratings of three Pharmaceutical stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Cornerstone Therapeutics’ (NASDAQ:CRTX) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Cornerstone Therapeutics is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products mainly for the respiratory and related markets. In Portfolio Grader’s specific subcategories of Earnings Revisions, Earnings Surprise, and Margin Growth, CRTX also gets an F. For more information, get Portfolio Grader’s complete analysis of CRTX stock.
This is a rough week for Depomed (NASDAQ:DEPO). The company’s rating falls to D from the previous week’s C. Depomed is a specialty pharmaceutical company focused on the development and commercialization of differentiated products that address large and growing markets and are based on proprietary oral drug delivery technologies. The stock gets F’s in Equity, Cash Flow, and Margin Growth. To get an in-depth look at DEPO, get Portfolio Grader’s complete analysis of DEPO stock.
This week, GlaxoSmithKline (NYSE:GSK) drops from C to a D rating. GlaxoSmithKline is a research-based pharmaceutical company. The stock also rates an F in Earnings Momentum. For a full analysis of GSK stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.